Search results for " Hodgkin Lymphoma"

showing 8 items of 8 documents

The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma

2016

// Alessandra Romano 1 , Nunziatina Laura Parrinello 1 , Calogero Vetro 1 , Daniele Tibullo 1 , Cesarina Giallongo 1 , Piera La Cava 1 , Annalisa Chiarenza 1 , Giovanna Motta 1 , Anastasia L. Caruso 1 , Loredana Villari 2 , Claudio Tripodo 3 , Sebastiano Cosentino 4 , Massimo Ippolito 4 , Ugo Consoli 5 , Andrea Gallamini 6 , Stefano Pileri 7 , Francesco Di Raimondo 1 1 Division of Hematology, AOU “Policlinico - Vittorio Emanuele”, University of Catania, Catania, Italy 2 Division of Pathology, AOU “Policlinico - Vittorio Emanuele”, Catania, Italy 3 Tumor Immunology Unit, Department of Health Science, University of Palermo, Palermo, Italy 4 Nuclear Medicine Center, Azienda Ospedaliera Cannizz…

0301 basic medicineMaleCancer ResearchMyeloidNeutrophilsmedicine.medical_treatmentArginase-1Treatment outcomeKaplan-Meier EstimateGastroenterology0302 clinical medicineHematologyHealthy subjectsImmunosuppressionHematologyMiddle AgedPrognosisHodgkin DiseaseTreatment Outcomemedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleArginase-1; Hodgkin Lymphoma; PET-2Tumor immunologyResearch PaperAdultmedicine.medical_specialtyPrognostic variableAdolescentAntineoplastic AgentsPET-2Sensitivity and SpecificityDisease-Free SurvivalYoung Adult03 medical and health sciencesInternal medicineBiomarkers TumormedicineHumansProgression-free survivalAgedArginasebusiness.industryMyeloid-Derived Suppressor Cells030104 developmental biologyPotential biomarkersImmunologyHodgkin lymphomabusinessHodgkin lymphoma030215 immunologyOncotarget
researchProduct

Follicular dendritic cells display microvesicle-associated LMP1 in reactive germinal centers of EBV+ classic Hodgkin lymphoma

2018

Expression of the latent membrane protein-1 (LMP1) of Epstein-Barr virus (EBV) was investigated in 153 cases of EBV+ classic Hodgkin lymphoma (cHL); 120 cases were pediatric patients (< 14 years of age) from Iraq, and 33 cases were adult patients from Italy. We describe for the first time the presence of LMP1 protein in EBV-encoded RNA (EBER)-negative follicular dendritic cells (FDCs) of reactive germinal centers (GC) associated with EBV+ cHL. Presence of LMP1+ GCs was independent of geographic region and age of patients. Variable numbers of reactive GCs were present in 22.2% of cases (34 of 153), whereas LMP1 staining of FDCs was present in about a third of cases (10 of 34) with reactiv…

0301 basic medicineMaleEpstein-Barr Virus InfectionsClassic Hodgkin lymphoma (cHL)CD30Follicular dendritic cells (FDCs)Exosomes and&nbsp0302 clinical medicineclassic hodgkin lymphoma (chl); epstein-barr virus (ebv); exosomes and microvesicles; follicular dendritic cells (fdcs); latent membrane protein-1 (lmp1); programmed death ligand 1 (pd-l1)Nodular sclerosisCell-Derived MicroparticlesEpstein-Barr Virus Infectionhemic and lymphatic diseasesChildCD63MicrovesicleGeneral MedicineMiddle AgedHodgkin DiseaseEpstein-Barr virus (EBV)Cell-Derived Microparticle030220 oncology & carcinogenesisProgrammed death ligand 1 (PD-L1)microvesicleOriginal ArticleFemaleHumanAdultBiologyVirusPathology and Forensic MedicineViral Matrix Proteins03 medical and health sciencesExosomes and microvesiclesmedicineotorhinolaryngologic diseasesHumansMolecular BiologyEpstein–Barr virus infectionAgedFollicular dendritic cellsGerminal centerCell Biologymedicine.diseaseGerminal CenterMolecular biologystomatognathic diseases030104 developmental biologyLatent membrane protein-1 (LMP1)Dendritic Cells Follicular
researchProduct

SETIL: Italian multicentric epidemiological case–control study on risk factors for childhood leukaemia, non hodgkin lymphoma and neuroblastoma: study…

2014

Background Aetiology of childhood leukaemia and childhood neoplasm is poorly understood. Information on the prevalence of risk factors in the childhood population is limited. SETIL is a population based case–control study on childhood leukaemia, conducted with two companion studies on non-Hodgkin Lymphoma (NHL) and neuroblastoma. The study relies on questionnaire interviews and 50 Hz magnetic field (ELF-MF) indoor measurements. This paper discusses the SETIL study design and includes descriptive information. Methods The study was carried out in 14 Italian regions (78.3% of Italian population aged 0–10). It included leukaemia, NHL and neuroblastoma cases incident in 0–10 year olds in 1998–20…

MalePediatricsPassive smokingLymphomaEpidemiologyNon hogdkin lymphomamedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataNeuroblastomaEconomicahemic and lymphatic diseasesEpidemiologyPrevalencerisk factorsLeukaemiaChildeducation.field_of_studyIncidence (epidemiology)IncidenceLymphoma Non-Hodgkinnon hodgkin lymphoma and neuroblastomaEnvironmental exposureItalyChild PreschoolPopulation studyFemaleHumanmedicine.medical_specialtyPopulationNon-HodgkinSocio-culturalestudy populationRisk Assessmentchildhood leukaemiamedicineHumanseducationPreschoolPregnancybusiness.industryResearchrisk factors; childhood leukaemia; non hodgkin lymphoma and neuroblastoma; study populationCase-control studyInfant NewbornAmbientaleInfantEnvironmental Exposuremedicine.diseaseNewbornbusiness
researchProduct

Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

2015

BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625, 000 adult patients diagnosed in 2000-2007 and followed up to 2008. Survival information was provided by 89 participati…

OncologyCancer registry; Europe; Hodgkin lymphoma; Leukaemia; Lymphoma; Multiple myeloma; Non-Hodgkin lymphoma; Relative survivalCancer Researcheducation.field_of_studymedicine.medical_specialtyMyeloidRelative survivalbusiness.industryPopulationFollicular lymphomaPlasma cell neoplasmmedicine.diseaseLymphomaCancer registrymedicine.anatomical_structureOncologyhemic and lymphatic diseasesInternal medicineImmunologyMedicineeducationbusinessInternational Classification of Diseases for OncologyEuropean Journal of Cancer
researchProduct

Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients

2017

Hodgkin Lymphoma (HL) is a tumor of B-cell origin characterized by Hodgkin and Reed-Stenberg (H/RS) cells embedded in an inflammatory tissue where numerous cytokines/chemokines contribute to shape the microenvironment, leading to the typical clinical symptoms. We investigated: i) the expression of Interleukin-IL-31 (IL-31) and Thymic Stromal Lymphopoietin (TSLP), two Th2-related cytokines with tumor-promoting and pruritogenic functions, and of the respective receptors in HL invaded lymph nodes by flow cytometry, and ii) the potential association of IL-31/TSLP plasma concentrations with clinical characteristics by ELISA. H/RS cells and the major immune cell types infiltrating HL lymph nodes …

0301 basic medicineChemokineThymic stromal lymphopoietinIL-31cytokine receptorsFlow cytometryCytokine receptors; Hodgkin lymphoma; IL-31; PET; TSLP; Oncology03 medical and health sciencesImmune systemcytokine receptors; hodgkin lymphoma; IL-31; pet; tslp; oncologyMedicineReceptorLymph nodebiologymedicine.diagnostic_testbusiness.industryCytokine receptorSettore MED/15 - MALATTIE DEL SANGUEPET030104 developmental biologyInterleukin 31medicine.anatomical_structureOncologyTSLPImmunologybiology.proteinLymphbusinessHodgkin lymphomaResearch PaperOncotarget
researchProduct

Whole-body MRI radiomics model to predict relapsed/refractory Hodgkin Lymphoma: A preliminary study.

2022

Purpose A strong prognostic score that enables a stratification of newly diagnosed Hodgkin Lymphoma (HL) to identify patients at high risk of refractory/relapsed disease is still needed. Our aim was to investigate the potential value of a radiomics analysis pipeline from whole-body MRI (WB-MRI) exams for clinical outcome prediction in patients with Hodgkin Lymphoma (HL). Materials and methods Index lesions from baseline WB-MRIs of 40 patients (22 females; mean age 31.7 ± 11.4 years) with newly diagnosed HL treated by ABVD chemotherapy regimen were manually segmented on T1-weighted, STIR, and DWI images for texture analysis feature extraction. A machine learning approach based on the Extra T…

AdultPositron emission tomographymedicine.medical_specialtyWhole body mriBiomedical EngineeringBiophysicsVinblastineBleomycinYoung AdultRefractoryRadiomicsPositron Emission Tomography Computed TomographyMachine learningAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRadiology Nuclear Medicine and imagingMagnetic resonance imaging Positron emission tomography Machine learning Texture analysis Hodgkin Lymphomamedicine.diagnostic_testHodgkin Lymphomabusiness.industryMagnetic resonance imagingMetabolic tumor volumeHodgkin DiseaseMagnetic Resonance ImagingDacarbazineTexture analysisPositron emission tomographyDoxorubicinRelapsed refractoryHodgkin lymphomaFemaleRadiologySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessMagnetic resonance imaging
researchProduct

Caecal leiomyoma detected by whole-body MRI in a patient with Hodgkin lymphoma: first case report

2017

Introduction. Hodgkin Lymphoma (HL) is one of the most curable malignant diseases. Modern treatments, like the combined radiochemotherapy and stem cell transplantation, have increased the number of malignant disease survivors. However, HL survivors are at risk of long-term effects, including the development of solid tumors. Secondary neoplasms are a major cause of late morbidity and mortality following treatment for HL. Case report. We report the case of a male patient, treated for HL by chemotherapy, who developed a large leiomyoma of the cecum one year after the treatment. A whole-body Magnetic Resonance (WBMRI) scan performed during the follow-up allowed the detection of this incidental …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentCecal NeoplasmsLaparoscopic surgeryBenign tumorLesionBiopsymedicineHumansWhole Body ImagingCaecal leiomyomaIncidental FindingsChemotherapyCaecal leiomyoma; Hodgkin lymphoma; Laparoscopic surgery; Magnetic resonance imaging; SurgeryLeiomyomamedicine.diagnostic_testbusiness.industryNeoplasms Second PrimaryMagnetic resonance imagingmedicine.diseaseHodgkin DiseaseMagnetic Resonance ImagingTransplantationSettore MED/18 - Chirurgia GeneraleLeiomyomaSurgeryOriginal ArticleRadiologyDifferential diagnosismedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedbusinessHodgkin lymphomaGiornale di Chirurgia - Journal of Surgery
researchProduct

Analysis of Metabolic Parameters Coming from Basal and Interim PET in Hodgkin Lymphoma

2018

Objective: Positron Emission Tomography (PET) with F-18-Fluoro-deoxy-glucose (FDG) emerged as a prognostic tool to predict treatment outcome in Hodgkin Lymphoma (HL). Moreover, a FDG-PET adapted strategy is currently assessed in clinical trial to minimize the toxic effect while maintaining the efficacy of treatment in HL. Purpose was to analyze the quantitative parameters to support the prognostic role of FDG-PET today based on the semi-quantitative Deauville 5-point Scale (D5-PS). Methods: This retrospective study included 53 patients diagnosed with advanced-stage HL between 2009 and 2014, enrolled in the PET response-adapted clinical trial HD 0607. FDG-PET was performed at baseline (PET0)…

Pathologymedicine.medical_specialtyChemothrapy; FDG PET; Hodgkin lymphoma; Metabolic parameters; Metabolic tumor volume; Prognostic value; Radiology Nuclear Medicine and Imagingbusiness.industryHODGkin lymphomaMetabolic tumor volume02 engineering and technology021001 nanoscience & nanotechnologyInterim pet03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineNuclear Medicine and ImagingFDG PETmedicineHodgkin lymphomaRadiology Nuclear Medicine and imaging030212 general & internal medicineMetabolic parametersRadiology0210 nano-technologyNuclear medicinebusinessPrognostic valueChemothrapyCurrent Medical Imaging Reviews
researchProduct